SILVER SPRING, Md., June 13, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of June 13, 2011.
FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations.
Meetings, Workshops and Congressional Testimony:
Friday, 6/17 – The Dermatologic and Ophthalmic Drugs Advisory Committee  discusses aflibercept ophthalmic solution, proposed trade name EYLEA, for treatment of neovascular age-related macular degeneration (wet AMD). 8 a.m., The Inn & Conference Center, University of Maryland College, 3501 University Blvd. East, Adelphi, Md.
Press Office Contact: Erica Jefferson, 301-796-4988, email@example.com 
FDA Office of Public Affairs Contact Information:
Call or email FDA Office of Public Affairs, 301-796-4540, firstname.lastname@example.org